Vertex Pharmaceuticals has delivered a remarkable 15.1% average annual return since its 1991 IPO, with a 10,310% growth, driven by its success in developing medicines for rare diseases, including cystic fibrosis. The company's focus on targeting underlying causes of diseases, combined with its innovation culture and vision, makes it a solid buy-and-hold-forever pick.